Investor Relations

News Release Details

RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference

Sep 26, 2018
- RXi to present a poster today, Wednesday, September 26, 2018
- Advancements in the Company's immuno-oncology programs will be presented demonstrating the potential of sd-rxRNA in NK cells for the use in adoptive cell therapy (ACT)
- Data further expands the broad applicability of sd-rxRNA for the development of cancer immunotherapies

MARLBOROUGH, Mass., Sept. 26, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform today announced that it will present a poster entitled, "The Use of Self-delivering RNAi to Enhance NK Cell Cytotoxicity," at the 16th Annual Discovery on Target Conference.  The conference is being held September 25-28, 2018 at the Sheraton Boston in Massachusetts.  

Logo - http://mma.prnewswire.com/media/594748/RXi_Pharmaceuticals_Corporation_Logo.jpg

Date:  Wednesday, September 26, 2018
Location:
  Sheraton Boston
Title:
The Use of Self-delivering RNAi to Enhance NK Cell Cytotoxicity
View the poster here:  http://investors.rxipharma.com/events-and-presentations/posters

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company's discovery and research efforts are focused on developing sd-rxRNA therapeutic compounds to be used with an Adoptive Cell Transfer (ACT) approach. This process uses immune cells, such as T-lymphocytes that are isolated from the patient or retrieved from allogeneic immune cell banks, and then expanded and in some cases processed to express tumor-binding receptors. Our approach introduces a new and important step in ex-vivo processing of the immune cells where sd-rxRNA is used to eliminate the expression of immunosuppressive receptors or proteins from the therapeutic immune cells, making them less sensitive to tumor resistance mechanisms and thus improving their ability to destroy the tumor cells. Essentially, we aim to maximize the power of our sd-rxRNA therapeutic compounds by weaponizing therapeutic immune effector cells to attack cancer and ultimately provide patients battling terminal cancers with a powerful new treatment option that goes beyond current treatment modalities.

For additional information, visit the Company's website, www.rxipharma.com and follow us on Twitter @RxiPharma.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including the safety and efficacy of our product candidates, future success of our clinical trials and scientific studies, our ability to enter into strategic partnerships and the future success of these strategic partnerships, the availability of funds and resources to pursue our research and development projects and general economic conditions. Our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q include detailed risks under the caption "Risk Factors" that may affect our business, results of operations and financial condition. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact RXi Pharmaceuticals Corporation
Tamara McGrillen
Tel: +1 508-929-3646
Email: tmcgrillen@rxipharma.com

Cision View original content:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-to-present-new-data-from-its-immuno-oncology-program-using-sd-rxrna-therapeutic-compounds-targeting-intracellular-checkpoint-cbl-b-in-nk-cells-at-the-16th-annual-discovery-on-target-conference-300719117.html

SOURCE RXi Pharmaceuticals Corporation